pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
APHP200034
Phase 1 · other · Non-ischemic Dilated Cardiomyopathies
APHP200034 for Non-ischemic Dilated Cardiomyopathies is a Phase 1 program (other) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code APHP200034
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 1
- Modality
- other
- Indication
- Non-ischemic Dilated Cardiomyopathies
- Status
- active
- Trials
- 1